Dr Alan Taylor, PhD
Executive Chairman
Alan joined the Board in November 2013 as Executive Chairperson.
Alan has been instrumental in the growth of the Company and has been heavily involved in all areas of the Company’s business. He has approximately 15 years of investment banking experience focused predominantly on the life sciences sector, and has significant expertise in capital raisings, mergers and acquisitions, and general corporate advisory. Prior to joining Clarity, Alan was an Executive Director of Inteq Limited, a boutique Australian investment bank.
After receiving the University Medal for his undergraduate degree in Applied Science at the University of Sydney, Alan completed his PhD in Medicine at the Garvan Institute of Medical Research. Dr Taylor has also completed a Graduate Diploma in Applied Finance at the Securities Institute of Australia.
Dr Colin Biggin, PhD
Managing Director, CEO
Colin joined the Board in October 2019 as Managing Director and CEO after playing an instrumental role in enhancing and designing the Company’s product development and clinical programmes since he first joined the Company in January 2017.
Colin has over 15 years of radiopharmaceutical development and commercialisation experience. Colin previously served with Algeta ASA during the development and commercialisation of its product Xofigo® (radium-223 dichloride) for metastatic prostate cancer, which was approved by the FDA in 2013. Prior to joining the Company, Colin also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals.
Colin holds a Bachelor of Science (Honours) and a PhD from the University of Glasgow.
Michelle Parker
Executive Vice President – Global Clinical Operations
Michelle joined the Company in June 2018 and is the Company’s Executive Vice President of Global Clinical Operations.
Michelle has over 20 years of experience spanning across nuclear medicine/PET and pharmaceutical industries both in Australia and internationally. Prior to joining the Company, Michelle held the position of Head of International Clinical Research Operations at Novartis Australia, a global pharmaceutical company, leading a multi-disciplinary, high performing team of over 35 associates responsible for end-to-end clinical trial execution.
Michelle holds a Bachelor of Applied Science in Medical Radiation Technology (Nuclear Medicine) from the University of Sydney.
Kathryn Williams Day
Vice President – Regulatory and Quality
Kat joined the Company in July 2023 and is Clarity’s VP of Regulatory and Quality.
She has twenty-plus years’ experience in the biotech and pharmaceutical industry. Kat has held global and affiliate positions across numerous therapeutic areas (oncology, multiple sclerosis, rare disease), building and leading regulatory and quality teams dedicated to making a difference for better patient outcomes. Throughout her career, Kathryn has held significant positions in notable companies such as Merck, Sandoz, Sanofi and Genzyme.
Shaemus Gleason
Executive Vice President – Operations
Shaemus joined the Company in May 2021 and is the Company’s Executive Vice President of Operations.
Shaemus has over 13 years of experience spanning across all facets of targeted radionuclide therapies and diagnostic radiopharmaceuticals. Prior to joining the Company, Shaemus was a member of the oncology strategy business unit at Bayer/Algeta where he was responsible for the technical operations in their phase I targeted alpha therapy development globally. Prior to this, he held a leadership role on the US commercial organisation supporting a marketed product Xofigo® (radium-223 dichloride) for metastatic prostate cancer.
Dr Matt Harris, PhD, MBA
Chief Technology Officer
Matt was part of the founding group, TM Ventures, and the first Managing Director from 2010 until 2018. He is currently Director of Technology at Clarity.
Matt has approximately 20 years of combined experience in cancer research, nuclear medicine and business and has a PhD in cancer research from the Australian National University. Matt brings expertise in biotechnology, radiopharmaceuticals, academic research and investment to the Company and focuses on developing the technology behind the Company’s products.
Matt has an MBA from the Australian Graduate School of Management. He has held leading managerial positions and director roles in several early stage Australian life science companies.
David Green
Chief Financial Officer
David joined the Company in January 2022 and is now serving as Clarity’s Chief Financial Officer responsible for the overall financial management of the Company including IT and HR.
David comes to the role with over 25 years’ experience in performing senior finance roles for listed and unlisted companies, including Pacific Dunlop Limited, Sigma Pharmaceuticals, Alchemia Limited, Chiquita Brands South Pacific Limited (now Costa Group) and Ellume Limited. David commenced his career with Ernst & Young in Australia and Europe.
As a proven CFO, David has extensive experience in complex operating environments across multiple geographies, private treaty and public company transactions, treasury operations and debt and equity markets.
David is a Chartered Accountant and holds a Bachelor of Economics (Monash University) and Masters of Applied Finance (Securities Institute of Australia).
Robert Vickery
Company Secretary
Robert joined the Company in July 2019 as Clarity’s Chief Financial Officer and is now serving as Company Secretary.
Robert is a finance and governance executive with over 30 years of experience and has had extensive involvement in life sciences and early stage businesses. Prior to joining the Company, Robert led the finance function at the previously ASX-listed company, Viralytics Limited, and was a key member of the due diligence target team during the trade sale negotiations and due diligence process with the purchaser of the company (Merck & Co), liaising with legal and investment banking teams, as well as leading the finance, IT and HR integration efforts post acquisition.
Robert holds a Bachelor of Commerce from the University of New South Wales and is an Associate